{
  "variant_id": {
    "Gene": "EGFR",
    "Protein_Change": {
      "ref": "L",
      "alt": "R",
      "position": "858"
    },
    "variant_string_id": "EGFR L858R"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The paper discusses EGFR mutations in NSCLC and their role in activating downstream signaling pathways.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly states that EGFR mutations lead to increased kinase activity and activation of downstream targets."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The paper uses a cell culture-based kinase activity assay to measure EGFR's autophosphorylation and downstream signaling.",
      "judgment": "Yes",
      "reasoning": "This assay is a standard technique in the field for studying EGFR mutations' effects on kinase activity."
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_moderate"
  },
  "overall_conclusion": "The final evidence strength for Variant 1 is therefore: Max PS3_moderate, based on the increased kinase activity associated with EGFR L858R compared to wild-type in a cell culture-based assay."
}